[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"sick-sinus-syndrome\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:sick-sinus-syndrome":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,54,79,102,135,167],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":32,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":42,"lastUpdatePostDateStruct":43,"startDateStruct":46,"completionDateStruct":48,"leadSponsor":50,"locationsCount":53},"100644473","comparison-of-focal-cryoablation-vs-radiofrequency-cardioneuroablation-for-bradyarrhythmias-100644473",false,"NCT07671898","Comparison of Focal Cryoablation vs. Radiofrequency Cardioneuroablation for Bradyarrhythmias","Prospective Non-Randomized Comparison of Point-by-Point Cryoablation Using Freezor™ Xtra Versus Radiofrequency Ablation Using TactiFlex™ SE of Parasympathetic Ganglia (Cardioneuroablation) in Patients With Vagally-Mediated Bradyarrhythmias","CRYO-CNA vs RF","Inclusion Criteria:\n\n* Age 18 to 60 years;\n* Symptomatic bradycardia (sinus bradycardia or bradycardia due to atrioventricular block, including transient);\n* Severe asymptomatic sinus bradycardia (heart rate less than 30 beats per minute);\n* Transient second- or third-degree atrioventricular block;\n* Persistent second-degree atrioventricular block;\n* Rhythm pauses greater than 6 seconds;\n* Recurrent syncope or presyncope with documented association with bradycardia (without trauma);\n* Positive response to atropine (heart rate increase ≥25% from baseline or \\>90 beats per minute) OR positive response to exercise (heart rate increase ≥25% from baseline or \\>90 beats per minute, OR conversion of second- or third-degree atrioventricular block to first-degree block or complete normalization of atrioventricular conduction during sinus rhythm);\n\nExclusion Criteria:\n\n* Chronic antiarrhythmic drug therapy (ongoing);\n* Presence of implanted pacemaker, cardiac resynchronization therapy device, or implantable cardioverter-defibrillator;\n* Bradyarrhythmia secondary to medications;\n* Bradyarrhythmia secondary to electrolyte imbalance (hyperkalemia);\n* Bradyarrhythmia secondary to hypothyroidism;\n* Bradyarrhythmia secondary to obstructive sleep apnea syndrome;\n* Absence of response to pharmacological denervation (no heart rate increase after atropine administration up to maximum dose of 0.2 mg\u002Fkg);\n* Clinically significant coronary artery disease;\n* Post-myocardial infarction cardiosclerosis;\n* Hemodynamically significant congenital heart disease (including surgically corrected);\n* Stable ventricular tachycardia in the setting of bradycardia;\n* History of stroke or transient ischemic attack;\n* Prior open-heart surgery;\n* Prior catheter-based coronary artery intervention or percutaneous coronary intervention;\n* Pregnancy or breastfeeding; Age less than 18 years Age greater than 60 years","ALL","18 Years","60 Years",{"count":21,"type":22},60,"ESTIMATED","INTERVENTIONAL",[25],"NA","Bradyarrhythmias are conditions where the heart beats too slowly, causing symptoms like dizziness, fainting, and fatigue. In some patients, these slow heart rhythms are caused by overactivity of the vagus nerve (the part of the nervous system that slows the heart down).\n\nCardioneuroablation (CNA) is a catheter-based procedure that targets and reduces the effect of these overactive nerves on the heart. It is an alternative to permanent pacemaker implantation, especially for younger patients.\n\nTraditionally, CNA is performed using radiofrequency (RF) energy to create small burns in specific areas of the heart. This study investigates whether focal cryoablation (freezing technology using the Freezor™ Xtra catheter) is as safe and effective as standard RF ablation for CNA.\n\nThis is a prospective, non-randomized study. Participants will receive either RF ablation (N=30) or cryoablation (N=30). The study will evaluate the recurrence of slow heart rhythms and fainting episodes, as well as any complications, over 12 months of follow-up.",[28,29,30,31],"Bradycardia","Syncope, Vasovagal","Sick Sinus Syndrome","Atrioventricular Block",[33,34,35,36,37,38,39,40,30,31],"Cardioneuroablation,","Cryoablation","Radiofrequency Ablation","Ganglionated Plexi","Parasympathetic Nervous System","Bradyarrhythmias","Functional Bradycardia","Vasovagal Syncope","RECRUITING","2026-06-22",{"date":44,"type":45},"2026-06-26","ACTUAL",{"date":47,"type":45},"2024-09-01",{"date":49,"type":22},"2028-12-25",{"name":51,"class":52},"Tomsk National Research Medical Center of the Russian Academy of Sciences","OTHER",1,{"id":55,"slug":56,"hasResults":11,"nctId":57,"briefTitle":58,"officialTitle":58,"acronym":59,"eligibilityCriteria":60,"healthyVolunteers":11,"sex":17,"minAge":61,"maxAge":4,"enrollmentInfo":62,"targetDuration":64,"studyType":65,"phases":4,"briefSummary":66,"conditions":67,"keywords":68,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":53},"100620626","prospective-cohort-study-of-bachmann-bundle-versus-right-atrial-appendage-pacing-impact-on-atrial-cardiomyopathy-evaluated-by-echocardiographic-parameters-and-clinical-outcome-100620626","NCT07360067","Prospective Cohort Study of Bachmann Bundle Versus Right Atrial Appendage Pacing: Impact on Atrial Cardiomyopathy Evaluated by Echocardiographic Parameters and Clinical Outcome","BRAVE","Inclusion Criteria:\n\n* Patients aged 19 years or older\n* Patients diagnosed with sick sinus syndrome who are scheduled for de novo implantation of a permanent pacemaker or permanent implantable cardioverter-defibrillator\n* Patients or their legal representatives who voluntarily consent to the access of medical records and study data throughout the entire research period\n\nExclusion Criteria:\n\n* Patients with persistent or permanent AF\n* Patients with a life expectancy of less than one year due to other comorbidities\n* Pregnant or breastfeeding women\n* Patients who refuse active treatment","19 Years",{"count":63,"type":22},200,"1 Year","OBSERVATIONAL","The goal of this observational study is to evaluate the impact of different atrial pacing sites-Bachmann's bundle pacing versus right atrial appendage pacing-on the development and progression of atrial cardiomyopathy in patients diagnosed with sick sinus syndrome who are undergoing permanent pacemaker implantation.",[30],[69],"bachmann bundle pacing","2026-01-14",{"date":72,"type":45},"2026-01-22",{"date":74,"type":45},"2025-12-09",{"date":76,"type":22},"2028-12-31",{"name":78,"class":52},"Samsung Medical Center",{"id":80,"slug":81,"hasResults":11,"nctId":82,"briefTitle":83,"officialTitle":84,"acronym":85,"eligibilityCriteria":86,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":87,"targetDuration":4,"studyType":23,"phases":89,"briefSummary":90,"conditions":91,"keywords":4,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":53},"100617083","left-bundle-branch-versus-minimized-ventricular-pacing-in-patients-with-sick-sinus-syndrome-and-prolonged-av-interval-100617083","NCT07314008","Left Bundle Branch Versus Minimized Ventricular Pacing in Patients With Sick Sinus Syndrome and Prolonged AV Interval","Comparison of Left Bundle Branch Area Pacing and Minimized Ventricular Pacing in Patients With Sinus Node Dysfunction and Atrioventricular Conduction Delay: A Multicenter, Randomized Controlled Clinical Trial","CLOSE-AV","Inclusion Criteria:\n\n* \\>18 years old\n* Sinus node dysfunction with symptoms\n* Atrioventricular conduction delay (PR interval \\> 200ms)\n\nExclusion Criteria:\n\n* Subject was unable to provide written informed consent or participate in long-term follow-up.\n* Permanent atrial fibrillation\n* Pre-existing cardiac implantable electronic device\n* Persistent advanced atrioventricular conduction disturbance (2:1 block, Mobitz type II, or 3rd degree)\n* Mechanical tricuspid valve\n* Ventricular septal defect or scar\n* Left ventricular ejection fraction \\\u003C 35% who indicated cardiac resynchronization therapy\n* Previous heart transplantation\n* Pregnant and\u002For lactating women\n* Life expectancy \\\u003C2 year\n* Patients who are actively participating in another drug or device investigational study, which have not completed the primary endpoint follow-up period",{"count":88,"type":22},440,[25],"The goal of this clinical trial is to compare two pacemaker strategies: Left Bundle Branch Area Pacing (LBBAP) and Minimized Ventricular Pacing (MVP) in patients requiring a permanent pacemaker for sick sinus syndrome and prolonged AV interval. It will also evaluate the safety and feasibility of the LBBAP method in these patients.\n\nThe main questions it aims to answer is:\n\n\\*Is LBBAP with physiological AV interval better than Minimized Ventricular Pacing?\n\nResearchers will compare the LBBAP group (aiming for conduction system capture with physiological AV intervals) to the MVP group (aiming to minimize ventricular pacing with prolonged AV intervals) to evaluate the optimal pacing strategy.\n\nParticipants will:\n\n* Be randomly assigned to either the LBBAP group or the MVP group.\n* Undergo a pacemaker implantation procedure according to the specific criteria for their assigned group.\n* Visit the clinic for regular checkups to measure pacing function and ensure the device settings remain compliant with the study protocol.",[30,92],"Atrioventricular Nodal Dysfunction","2025-12-23",{"date":95,"type":45},"2026-01-02",{"date":97,"type":45},"2025-05-02",{"date":99,"type":22},"2029-01-31",{"name":101,"class":52},"Asan Medical Center",{"id":103,"slug":104,"hasResults":11,"nctId":105,"briefTitle":106,"officialTitle":107,"acronym":108,"eligibilityCriteria":109,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":110,"targetDuration":112,"studyType":65,"phases":4,"briefSummary":113,"conditions":114,"keywords":116,"overallStatus":125,"whyStopped":4,"lastUpdateSubmitDate":126,"lastUpdatePostDateStruct":127,"startDateStruct":129,"completionDateStruct":131,"leadSponsor":133,"locationsCount":53},"100614408","pace-af-prospective-analysis-of-cardiac-electrostimulation-and-atrial-fibrillation-100614408","NCT07279207","PACE-AF: Prospective Analysis of Cardiac Electrostimulation and Atrial Fibrillation","Prospective Analysis of Cardiac Electrostimulation and Atrial Fibrillation (PACE-AF)","PACE-AF","Inclusion Criteria:\n\n* • Age ≥ 18 years\n\n  * Implantation of a dual-chamber permanent pacemaker\n  * Ability to provide informed consent\n  * Willingness to participate in long-term follow-up\n\nExclusion Criteria:\n\n* • Single-chamber pacemaker or Cardiac Resynchronization Therapy device at baseline\n\n  * Life expectancy \\\u003C 1 year due to non-cardiac comorbidities\n  * Inability to comply with follow-up visits or device interrogation\n  * Participation in another clinical trial that could interfere with study endpoints",{"count":111,"type":22},500,"3 Years","PACE-AF is a prospective, observational patient registry designed to evaluate the impact of pacemaker algorithms on atrial fibrillation (AF) incidence, progression, and clinical outcomes in patients implanted with dual-chamber pacemakers. The registry aims to include 400-500 patients with longitudinal follow-up. Primary outcomes are progression to permanent AF and all-cause mortality. Secondary outcomes include quality of life, hospitalization, and cardiovascular events.",[115,30,31],"Atrial Fibrillation",[117,118,119,120,121,122,123,34,124],"Pacemaker","Dual-chamber pacing","Pacemaker algorithms","Conduction system pacing","His bundle pacing","Left bundle branch pacing","Catheter ablation","Arrhythmia prevention","NOT_YET_RECRUITING","2025-11-30",{"date":128,"type":45},"2025-12-12",{"date":130,"type":22},"2025-12",{"date":132,"type":22},"2028-12",{"name":134,"class":52},"Ilya Lukin",{"id":136,"slug":137,"hasResults":11,"nctId":138,"briefTitle":139,"officialTitle":140,"acronym":141,"eligibilityCriteria":142,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":143,"targetDuration":4,"studyType":23,"phases":145,"briefSummary":146,"conditions":147,"keywords":150,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":157,"lastUpdatePostDateStruct":158,"startDateStruct":160,"completionDateStruct":162,"leadSponsor":164,"locationsCount":166},"100566251","evaluating-the-safety-and-effectiveness-of-5g-cloud-follow-up-for-cardiovascular-implantable-electronic-devices-100566251","NCT06652750","Evaluating the Safety and Effectiveness of 5G Cloud Follow-up for Cardiovascular Implantable Electronic Devices","Evaluating the Safety and Effectiveness of 5G Cloud Follow-up for Cardiovascular Implantable Electronic Devices: a Prospective, Paired, Self-controlled, Non-inferiority, Multicenter Clinical Trial","CIED-CARE","Inclusion Criteria:\n\n1. Age ≥ 18 years, gender unspecified;\n2. Patients who have not undergone their first clinic follow-up after the implantation of cardiovascular implantable electronic devices (CIED); Note: In this study, CIED includes pacemakers, implantable cardioverter defibrillators (ICD), cardiac resynchronization therapy pacemakers (CRT-P) and defibrillators (CRT-D), excluding implantable cardiac event recorders (ICM) and implantable cardiovascular monitors.\n3. Willing to participate in this clinical study and have signed the informed consent form in writing.\n\nExclusion Criteria:\n\n* Exclusion Criteria:\n\nIf meeting any of the following, the individual cannot be included:\n\n1. Life expectancy \\\u003C 1 year.\n2. Inability to cooperate with treatment or follow-up, such as having mental illness.\n3. Participated in other clinical studies within 30 days before enrollment. Other situations that the researcher deems unsuitable for inclusion.",{"count":144,"type":22},688,[25],"Objective: This clinical study employs a prospective, paired, self-controlled, non-inferiority, multicenter research design to assess the safety and efficacy of utilizing 5G cloud follow-up for CIED in parameters monitoring and remote programming post-implantation.\n\nParticipants will:\n\nundergo regular clinic follow-up visits in accordance with the guidelines undergo routine in-office follow-up and 5G cloud follow-up during each regular clinic visit",[30,148,149],"Atrioventricular Block, Second and Third Degree","Heart Failure",[151,152,153,154,155,156],"pacemaker","implantable cardioverter defibrillator","cardiac resynchronization therapy","follow up","remote programming","in-office follow-up","2024-11-18",{"date":159,"type":45},"2024-11-21",{"date":161,"type":45},"2024-11-13",{"date":163,"type":22},"2026-02-01",{"name":165,"class":52},"The Third People's Hospital of Chengdu",2,{"id":168,"slug":169,"hasResults":11,"nctId":170,"briefTitle":171,"officialTitle":172,"acronym":173,"eligibilityCriteria":174,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":175,"enrollmentInfo":176,"targetDuration":4,"studyType":23,"phases":178,"briefSummary":179,"conditions":180,"keywords":182,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":187,"lastUpdatePostDateStruct":188,"startDateStruct":190,"completionDateStruct":191,"leadSponsor":193,"locationsCount":53},"100538269","cardioneuroablation-for-bradyarrhythmia-100538269","NCT06288633","Cardioneuroablation for Bradyarrhythmia","Cardioneuroablation for Bradyarrhythmia (Sinus Node and Atrioventricular Node Dysfunction): a Sham-controlled Randomised Multicentre Trial","CARDIOBOOST","Inclusion Criteria:\n\n1. Any of the following variants of bradyarrhythmia in patients aged 18-65 years:\n\n   (1.1.) Symptomatic sinus bradycardia or bradycardia due to atrioventricular blockade, including transient.\n\n   (1.2.) Severe asymptomatic sinus bradycardia with a rhythm frequency of \\\u003C30 beats\u002Fmin.\n\n   (1.3.) Transient atrioventricular block of II-III degree or permanent block of II degree.\n\n   (1.4.) Repeated fainting or pre-fainting states with a proven association with bradycardia (without injury).\n\n   (1.5.) Rhythm pauses \\>6 seconds.\n\n   In combination with the following two criteria:\n2. Positive reaction to physical activity and\u002For atropine test:\n\n   (2.1.) Increase in sinus rhythm frequency ≥25% or \\>90 beats\u002Fmin. (2.2.) The transition of atrioventricular blockade of the II-III degree to the 1st degree or complete normalization of atrioventricular conduction at the sinus rhythm.\n3. Sinus rhythm at the time of switching on\n\nExclusion Criteria:\n\n1. Anamnesis of injury during syncopation due to bradycardia, except in the case when the patient refused to implant an electrocardiostimulator for his own reasons in writing;\n2. Constant intake of antiarrhythmic drugs (for PVC, AF, etc.);\n3. The presence of an implanted pacemaker, a heart contractility modulation device, a cardioverter defibrillator;\n4. Drug-induced sinus bradycardia and\u002For atrioventricular block;\n5. Bradycardia due to electrolyte imbalance (e.g. hyperkalemia);\n6. Bradycardia due to hypothyroidism or other reversible conditions;\n7. No reaction to the administration of atropine (up to a maximum dose of 0.2 mg \u002F kg);\n8. Proven association of bradyarrhythmia with episodes of apnea\u002Fhypopnea in obstructive sleep apnea syndrome;\n9. Clinically significant coronary artery disease;\n10. Postinfarction cardiosclerosis;\n11. Hemodynamically significant congenital heart defects, including operated ones;\n12. Stroke or transient ischemic attack \\\u003C3 months;\n13. Open heart surgery in the anamnesis;\n14. Catheter interventions on coronary arteries or for cardiac arrhythmias \\\u003C3 days;\n15. Conditions after percutaneous coronary angioplasty \\\u003C3 months;\n16. Anamnesis of stable ventricular tachycardia on the background of bradycardia;\n17. Pregnancy or breastfeeding period","65 Years",{"count":177,"type":22},106,[25],"This is a multicenter prospective randomized blind controlled trial with a sham procedure group of the efficacy and safety of cardioneuroablation as a method of treating symptomatic bradycardia without a permanent pacemaker implantation",[28,181,30],"Syncope",[183,184,185,186],"bradycardia","cardioneuroablation","sinus node dysfunction","atrioventricular node dysfunction","2024-03-04",{"date":189,"type":45},"2024-03-05",{"date":187,"type":45},{"date":192,"type":22},"2027-02-01",{"name":194,"class":52},"Federal State Budgetary Institution, V. A. Almazov Federal North-West Medical Research Centre, of the Ministry of Health"]